Recent Trends in Diagnosis and Control of Mareks Disease (MD) in Poultry
Shambhu Dayal Singh,
Amit Kumar Verma
Mareks Disease (MD), caused by Mareks Disease Virus (MDV) is a highly contagious oncogenic and neuropathic disease of chickens responsible for great economic losses to the poultry industry all around the world and characterized by development of CD4+T cell lymphomas as well as infiltration of nerves and visceral organs by lymphocytes. MD is one of the most common lymphoproliferative diseases of chickens which cause mononuclear cell infiltration in one or more of the following tissues: peripheral nerves, gonads, lymphoid organs, iris, muscle, skin and other visceral organs resulting into development of tumours in visceral organs, paralysis of legs, wings and neck, grey eye (iris) or irregular pupil, vision impairment, blindness, skin lesions and immunosuppression, all of which can be accompanied by non-specific signs such as anorexia, weight loss and poor performance. Today there are evolving highly pathogenic isolates of MDV around the world capable of overwhelming the protection from currently employed vaccines. Thus MD poses a big challenge to the welfare and wellbeing of the poultry with increased condemnation of carcass, loss of productivity and quality products, leading to huge economic losses. It is also an immunosuppressive disease and causes increased susceptibility to other infections. The present review discusses in brief about the Mareks disease, its etiology, conventional and advance tools and techniques being used for its diagnosis, prevention and control strategies in poultry.
Received: November 13, 2012;
Accepted: January 28, 2013;
Published: March 06, 2013
Mareks Disease (MD) is caused by Mareks Disease Virus (MDV) and
it is a highly contagious oncogenic and neuropathic disease of chickens responsible
for great economic losses to the poultry industry worldwide. Sporadic outbreaks
of MD have been reported recently throughout the world even in vaccinated flocks
(Powell and Lombardini, 1986; Kuria
et al., 2001; Okwor and Eze, 2011; Lobago
and Woldemeskel, 2004), including India (Rajkhowa,
2005; Bineesh et al., 2007; Jadhav
et al., 2007; Kamaldeep et al., 2007;
Raja et al., 2009; Arulmozhi
et al., 2011; Gopal et al., 2012).
The disease is characterized by development of CD4+ T cell lymphomas as well as infiltration of nerves and visceral organs by lymphocytes.
Dr. Jozsef Marek first recognized the disease as a paralysis of roosters in
the year 1907. MD almost devastated the poultry industry in the 1960s but the
disease was brought under control after Marek's disease Herpes Virus of Turkey
(HVT) was identified and live vaccines were developed in 1970s. Thereafter,
variant MD viruses evolved with increased pathogenicity. Subsequently, many
MD outbreaks have been reported worldwide and new vaccines developed to combat
MD viruses with higher virulence. Earlier it is considered as paralytic disease
but now-a-days, it is manifested as an acute disease with tumours in multiple
visceral organs. Today there are evolving highly pathogenic isolates of MDV
around the world capable of overwhelming the protection from currently employed
vaccines. Thus, MD poses a big challenge to the welfare and wellbeing of the
poultry with increased condemnation of carcass, loss of productivity and quality
products, leading to huge economic losses. It is also an immunosuppressive disease
and causes increased susceptibility to other infections.
ETIOLOGICAL AGENT (MDV)
The causative agent of the diseases is Mareks Disease Virus (MDV) and
as per the recent classification by the International Committee on Taxonomy
of Viruses (ICTV, 2011), it is placed in Order Herpesvirales,
family Herpesviridae, subfamily Alphaherpesvirinae and genus Mardivirus (Mareks
disease-like viruses). MDV is a cell associated herpes virus consisting of a
linear, double stranded DNA of 160-180 kbp in size. MDV-Herpes virus group has
been divided into three serotypes based on their biological properties viz.
serotype 1, 2 and 3. Serotype 1 MDV is virulent and oncogenic whereas serotype
2 and 3 (HVT) are non-pathogenic vaccine strains. Serotype 1 MDV strain viruses
are further classified into pathotypes (Witter et al.,
2005) based on induction of lymphoproliferative lesions and severity of
disease in vaccinated chickens (Table 1).
CONVENTIONAL MD DIAGNOSIS
Primary diagnosis is based on age, clinical signs, history and gross and microscopic
lesions. Diagnosis of MD is easier in general in chickens younger than 14 weeks
of age, although non-bursal tumors could be caused by REV which must be excluded.
However, REV non-bursal tumors are generally not recorded in commercial flocks
below 14 weeks of age. Lymphoid leukosis is the most likely to be diagnosed
in older birds with bursal tumors, but MD virus and REV both can cause bursal
tumors. Occurrence of tumours in older birds in the absence of bursal tumors,
MD is the most probable diagnosis. Grossly, the disease is characterized by
paralysis of legs (Fig. 1), wings and neck, and tumour nodules
in visceral organs (Fig. 2) depending upon the tissue or organ
involved. Other observations include grey eye (iris) or irregular pupil, vision
impairment, blindness, skin lesions and immunosuppression.
|| Classification of MDV serotypes and their representative
||MD affected layer bird with unilateral leg paralysis displaying
|| MD lesions in liver with numerous greyish-white coalescing
Microscopically, mononuclear cell infiltration in one or more of the following
tissues: peripheral nerves, gonads, lymphoid organs, iris, muscle, skin and
other visceral organs (Fig. 3, 4, 5)
is observed. Laboratory confirmation is done by virus isolation in susceptible
(newly hatched) chicks, embryonated eggs and tissue cultures and subsequent
identification (Kataria et al., 2005). MDV can
be isolated in chicken embryos by yolk sac route (4-5 days embryo) and later
examining their chorioallantoic membranes (CAM) on 18th day of incubation for
the pock lesions (whitish raised nodules). Infected embryos also
show atrophy of muscles and curling. MD virus can also be isolated in Duck Embryo
Fibroblast (DEF) and chicken kidney cell culture systems. After 5-14 days, plaque
formation or cytopathic effects (CPE) are observed in cell culture. Type A intranuclear
inclusion bodies can be noticed in infected cells. Serotype can be confirmed
by using specific monoclonal antibodies.
||Numerous foci of transformed lymphocytes in the parenchyma
of liver. HE x100.
||Pleomorphic lymphocytes infiltrating the parenchyma of kidney.
||MD lesions in sciatic nerve: marked mononuclear cells infiltration
(Type A lesion). HE x400
Viral antigen can be detected in feather tips, follicle epithelium and infected
lymphoid tissue by Agar Gel Precipitation Test (AGPT), Fluorescent Antibody
Technique (FAT), Immunoperoxidase Test (IPT) and Enzyme-linked Immunosorbent
Assay (ELISA) (Schat and Nair, 2008). Demonstration of
Mareks disease Associated Tumour Surface Antigen (MATSA) on the transformed
cells can be of limited diagnostic value since activated T-cells also express
this protein. Immunohistochemistry can be effectively used to demonstrate MDV
proteins especially Meq oncoprotein which is consistently expressed
in all MD tumours.
RECENT ADVANCES IN MD DIAGNOSIS
Polymerase chain reaction (PCR)
PCR: The full length genomic sequences of MDV 1 (GenBank accession numbers:
strain Md5; AF243438, GA; AF147806, Md11; AY510475, CVI988; DQ530348), MDV 2
(GenBank accession numbers: strain SB-1; HQ840738, HPRS24; AB049735 (Izumiya
et al., 2001) and MDV 3 (GenBank accession number: strain FC126;
AF291866) are available now. This enables the PCR-based diagnostic methods for
serotype specific detection of MDV. PCR tests enabling differentiation of oncogenic
and non-oncogenic strains of MDV serotype and MDV vaccine strains of serotypes
2 and 3 (Becker et al., 1992; Zhu
et al., 1992; Handberg et al., 2001).
PCR tests to detect MDV 1 specific meq oncogene (Fig. 6)
in feathers and tumours have been published (Lee et
al., 2000; Chang et al., 2002).
||PCR for detection of 683 bp amplicon of MDV-1 genome
Nested PCR: Specific detection of meq oncogene of MDV 1 in infected
spleen cells, feather tips and peripheral blood mononuclear cells by nested
PCR have been developed (Lee et al., 2000; Murata
et al., 2007).
Multiplex PCR: Simultaneous detection of MDV 1, avian leukosis virus
and reticuloendotheliosis virus in tumour tissues of naturally infected chickens
and turkeys has been developed using multiplex PCR (Gopal
et al. 2012).
Quantitative real-time PCR (qPCR): qPCR to quantify MDV genome copies
have been described for simultaneous detection and quantitation of viral load
in clinical samples or infected tissues (Islam et al.,
2004; Baigent et al., 2005; Abdul-Careem
et al., 2006). Since MDV 1 is ubiquitous, its quantitation in suspected
clinical samples will be of diagnostic value rather than mere detection by PCR.
The qPCR can also be used to monitor the MD vaccines.
Loop mediated isothermal amplification technique (LAMP): Loop-mediated
isothermal amplification (LAMP) technique for rapid detection of MDV meq gene
in feathers of affected birds has been developed lately (Wozniakowski
et al., 2011; Angamuthu et al., 2012;
Wei et al., 2012). LAMP test required 100 fold
less copy number for detection of MDV compared to conventional PCR, and the
detection time can be less than sixty minutes (Wei et
al., 2012). The LAMP technique utilizes three different sets of primers
binding to six different sequences thus adding more specificity, the reaction
is carried out at isothermal conditions and the products can be visualized by
the naked eye (Notomi et al., 2000; Goto
et al., 2009).
Use of FTA filter cards for sample collection: The Flinders Technology Associates (FTA®) filter cards are now used in the field for collection, storage and transport of clinical samples for different purposes. The FTA cards are easily available and inexpensive. The FTA cards have been used to quantify Mareks Disease Virus (MDV) DNA for the diagnosis of Mareks Disease (MD) and to monitor MD vaccines. Samples of blood, solid tumors, and feather pulp collected in FTA paper have been successfully used for detection and quantitation of MDV genome by qPCR. The results of that study showed that FTA cards are an excellent media to collect, transport and store the samples for MD diagnosis and to monitor MD vaccines.
The three grossly similar-looking diseases MD, Lymphoid Leukosis (LL) and reticuloendotheliosis
(RE) should be differentially diagnosed. The MDV infection is ubiquitous, but
the disease is not. The principal methods to identify the presence of infection
are isolation of the MDV virus, demonstration of viral DNA or antigens in tissues,
and detection of antibody (Schat and Nair, 2008). Infection
by MDV in a flock may be detected by isolating the virus from the tissues of
infected chickens. However, the ubiquitous nature of MDV must be taken into
consideration and the diagnosis of MD should be based on a combination of MDV
isolation or detection of the genome by very sensitive Polymerase Chain Reaction
(PCR) and clinical disease (Zelnik, 2004; Schat
and Nair, 2008).
Since MDV and ALV viruses are ubiquitous mere detection of their nucleic acid in clinical samples is of limited value unless the virus specific antigen/oncoprotein is also demonstrated in infected/tumour cells by immunohistochemistry. qPCR technique can be used effectively to detect and quantitate the viral copy numbers. Exclusion of ALV and REV when others signs of MD are present will have diagnostic value. Ruling out other disease may help rather than ruling in because of the omnipresent nature of MDV and ALV. As far as REV is concerned detection of viral nucleic acids in tumours is of diagnostic value since the virus is not ubiquitous. The use of B or T cell marker monoclonal antibodies for immunophenotyping of tumour cells is not that useful in differential diagnosis since bursal B cell tumour can be caused by both ALV and REV, and non-bursal tumours caused by REV are CD8 positive T cells.
PREVENTION AND CONTROL
Control of the disease can be achieved by adapting good management practices and vaccination. Chicks should be reared in isolation for 2-3 months from older stocks. Removal of used litter and disinfection of buildings are important to control the disease. Strict bio-security is to be followed to avoid introduction of MDV in the flock. There is no treatment exists for Mareks disease. Vaccination has been the main approach for its prevention and control throughout the world. Vaccinal immunity, once acquired, is apparently lifelong. However, while vaccination will prevent clinical disease and reduces amount of infective virus shedding thus reducing horizontal disease spread, it will not prevent infection/transmission of the virus. Good management practices along with emphasis on all-in/all-out production, improved sanitation and hygiene, strict biosecurity measures and exploring genetic approaches for increasing the genetic resistance of birds are valuable measures for controlling MD. Genetic selection strategies for MHC have provided with chicken breeds/strains that are MD-resistant (B21) and MD-susceptible (B19).
MDV vaccination: past, present and future: MD vaccines are highly effective, often achieving more than 90% protection under commercial conditions. Herpes virus of turkey strain FC-126 is widely used and is highly effective against virulent MD virus. A bivalent vaccine consisting of HVT and a serotype-2 strain SB-1 have been found to have synergistic effect and provide better protection against virulent MDV. In-ovo vaccination is the method of choice due to no requirement of chick handling. Immunity develops within two weeks. Because vaccination does not prevent infection with the virus, the MDV has evolved with increased virulence and resistance to this vaccine. As a result, current vaccines used are a combination of vaccines using HVT and gallid herpesvirus type 3 or attenuated MDV strain, CVI988/Rispens.
The first Mareks disease vaccine was described by Churchill
et al. (1969) shortly after identification of causative of MD, a
cell-associated herpesvirus (Churchill and Biggs, 1967).
This vaccine was based on the oncogenic HPRS-16 strain of serotype 1 MDV (MDV-1)
that had been attenuated by serial passages using chicken kidney cell cultures.
It was licensed in the UK in 1970, but was soon replaced by a new vaccine, based
on herpes virus of turkey (HVT, strain FC-126) (Okazaki
et al., 1970; Witter et al., 1970).
The widespread vaccination provided the host with another important weapon against
the virus and the losses from the disease decreased dramatically by over 99%
(Witter, 2001). HVT-based vaccines are still widely
used, either alone or in association with other vaccine serotypes. In India,
Serotype 2 (SB-1) and 3 (HVT) vaccines are still in use (Morrow
and Fehler, 2004). An attenuated MDV strain, CVI988, is considered to be
the most protective vaccine currently available and has been introduced in many
countries (Davison and Nair, 2004). MDV vaccines are
administered in ovo at Embryonation Day (ED) 18. The automatic injectors
deposit the vaccine inoculum into the amniotic fluid of the majority of the
eggs. However, with increase in cases of vaccination failure and the emergence
of more virulent pathotypes, the disease poses a severe threat to the poultry
industry and challenge the control strategies (Venugopal
et al., 2000). Though MD vaccines have efficacy more than 95% (Witter,
1998), they have many inherent drawbacks (Nair, 2005).
The most important one is their inability to induce a sterile immunity
in the vaccinated host. This allows the virulent virus strains to replicate
and be shed into the environment in spite of the vaccination status of the host.
CVI988/Rispens (attenuated MDV 1) vaccine is useful in turkeys against MD, but
HVT was not protective against MD in this species (Schat
and Nair, 2008).
Recently, it was found that meq oncogene deleted recombinant vvMDV strain (rMd5ÄMeq)
could not induce tumours in infected chickens confirming that Meq oncoprotein
is essential for transformation of lymphocytes (Lupiani
et al., 2004). Two different experiments showed that rMd5ΔMeq
virus was fully attenuated after deletion of meq gene and the Meq-null
virus provided protection equal or superior to CVI988/Rispens (attenuated MDV
1), the most efficacious vaccine presently available against MD, following challenge
with very virulent (rMd5) and very virulent plus (648A) MDV strains (Chang
et al., 2011; Li et al., 2011). Further
research is needed to utilize them for field conditions. Molecularly defined
recombinant MDV vaccines eliciting sterile immunity will be the future as far
as MDV vaccine research is concerned.
CONCLUSION AND FUTURE PERSPECTIVES
Mareks disease is a disease of chickens produced by a herpesvirus that produces a reduction in the immune response in acutely infected birds followed by the production of tumours in many of the infected birds. Very virulent strains (vvMDV+) have been reported in a number of countries around the world and have affected broilers, breeders and commercial layers. This disease extensively limits the productivity of both egg producing and meat producing birds resulting in great economic impact in poultry industry. Vaccination, in conjunction with good farm cleaning and disinfection, proper reception practices, adequate downtime between flocks, all-in/all-out policy, accurate vaccination programs adapted to the type of bird and field situation, good vaccine preparation and administration practices and strict biosecurity measures can greatly reduce the incidence of Mareks disease and thereby prevent the economic losses due to the disease. In problematic areas with monovalent vaccine, bivalent or polyvalent vaccine is recommended for the effective prevention of virulent MDV. However, vaccine failures do occur as field strains continue to evolve towards pathotypes of greater virulence. The constant evolution of MDV has pressed us for the development of new vaccines or vaccine strategies that control the more virulent emerging strains. However, the competition between the development of vaccines and evolution of MDV is a major threat for poultry industry.
Abdul-Careem, M.F., B.D. Hunter, E. Nagy, L.R. Read, B. Sanei, J.L. Spencer and S. Sharif, 2006.
Development of a real-time PCR assay using SYBR Green chemistry for monitoring Marek's disease virus genome load in feather tips. J. Virol. Methods, 133: 34-40.CrossRef | PubMed | Direct Link |
Angamuthu, R., S. Baskaran, D.R. Gopal, J. Devarajan and K. Kathaperumal, 2012.
Rapid detection of the Marek's disease viral genome in chicken feathers by loop-mediated isothermal amplification. J. Clin. Microbiol., 50: 961-965.CrossRef | PubMed | Direct Link |
Arulmozhi, A., S. Saravanan, B. Mohan and G.A. Balasubramaniam, 2011.
Marek's disease in vaccinated poultry flocks in and around Namakkal region of Tamil Nadu. Indian J. Vet. Pathol., 35: 45-47.Direct Link |
Baigent, S.J., L.J. Petherbridge, K. Howes, L.P. Smith, R.J.W. Currie and V.K. Nair, 2005.
Absolute quantitation of Marek's disease virus genome copy number in chicken feather and lymphocyte samples using real-time PCR. J. Virol. Methods, 123: 53-64.CrossRef |
Becker, Y., Y. Asher, E. Tabor, I. Davidson, M. Malkinson and Y. Weisman, 1992.
Polymerase chain reaction for differentiation between pathogenic and non-pathogenic serotype 1 Marek's Disease Viruses (MDV) and vaccine viruses of MDV-serotypes 2 and 3. J. Virol. Methods, 40: 307-322.CrossRef |
Bineesh, P.P., S.K. Kansal, H.S. Banga, S. Sharma and R.S. Brar, 2007.
Prevalence and pathology of concurrent lung affections in the lymphoproliferative disorders of chicken. Indian Vet. J., 84: 911-914.Direct Link |
Chang, K.S., S.I. Lee, K. Ohashi, A. Ibrahim and M. Onuma, 2002.
The detection of the meq gene in chicken infected with marek's disease virus serotype 1. J. Vet. Med. Sci., 64: 413-417.PubMed | Direct Link |
Chang, S., Z. Ding, J.R. Dunn, L.F. Lee and M. Heidari et al
Comparative evaluation of the protective efficacy of rMd5deltaMeq and CVI988/ Rispens against a vv+ strain of Marek's disease virus infection in a series of recombinant congenic strains of White Leghorn chickens. Avian Dis., 55: 384-390.Direct Link |
Churchill, A.E. and P.M. Biggs, 1967.
Agent of Marek's disease in tissue culture. Nature, 215: 528-530.CrossRef |
Churchill, A.E., L.N. Payne and R.C. Chubb, 1969.
Immunization against Marek's disease using a live attenuated virus. Nature, 221: 744-747.CrossRef | Direct Link |
Davison, F. and V. Nair, 2004.
Marek's Disease: An Evolving Problem. Elsevier Academic Press, Oxford, ISBN: 9780080479187, Pages: 208
Gopal, S., P. Manoharan, K. Kathaperumal, B. Chidambaram and K.C. Divya, 2012.
Differential detection of avian oncogenic viruses in poultry layer farms and turkeys by use of multiplex PCR. J. Clin. Microbiol., 50: 2668-2673.CrossRef | Direct Link |
Goto, M., E. Honda, A. Ogura, A. Nomoto and K. Hanaki, 2009.
Colorimetric detection of loop-mediated isothermal amplification reaction by using hydroxy naphthol blue. Biotechniques, 46: 167-172.CrossRef | PubMed | Direct Link |
Handberg, K.J., O.L. Nielsen and P.H. Jorgensen, 2001.
The use of serotype 1- and serotype 3-specific polymerase chain reaction for the detection of Marek's disease virus in chickens. J. Virol., 30: 243-249.CrossRef | Direct Link |
Virus Taxonomy: 2011 Release (current). http://ictvonline.org/virusTaxonomy.asp?version=2011&bhcp=1.
Islam, A., B. Harrison, B.F. Cheetham, T.J. Mahony, P.L. Young and S.W. Walkden-Brown, 2004.
Differential amplification and quantitation of Marek's disease viruses using real-time polymerase chain reaction. J. Virol. Methods, 119: 103-113.CrossRef | PubMed | Direct Link |
Izumiya, Y., H.K. Jang, M. Ono and T. Mikami, 2001.
A complete genomic DNA sequence of Marek's disease virus type 2 strain HPRS24. Curr. Topics Microbiol. Immunol., 255: 191-221.PubMed | Direct Link |
Jadhav, M.M., P.D. Shelar, P.S. Patil, R.V. Dhumal, D.S. Suryawanshi and R.S. Nehete, 2007.
Pathological studies in Marek's disease outbreak in layers. J. Bombay Vet. College, 15: 4-6.Direct Link |
Kamaldeep, P.C. Sharma, N. Jindal and G. Narang, 2007.
Occurrence of marek`s disease in vaccinated poultry flocks of Haryana (India). Int. J. Poult. Sci., 6: 372-377.CrossRef | Direct Link |
Kuria, J.K., R.G. Wahome and P.K. Gitao, 2001.
An account of a recent outbreak of Marek' disease in Kenya. Kenya Vet., 21: 34-36.Direct Link |
Lee, S.I., M. Takagi, K. Ohashi, C. Sugimoto and M. Onuma, 2000.
Difference in the meq gene between oncogenic and attenuated strains of Marek's disease virus serotype 1. J. Vet. Med. Sci., 62: 287-292.CrossRef | PubMed | Direct Link |
Lobago, F. and M. Woldemeskel, 2004.
An outbreak of Marek's disease in chickens in Central Ethiopia. Trop. Anim. Health Prod., 36: 397-406.Direct Link |
Lupiani, B., L.F. Lee, X. Cui, I. Gimeno and A. Anderson et al
Marek's disease virus-encoded Meq gene is involved in transformation of lymphocytes but is dispensable for replication. Proc. Nat. Acad. Sci. USA, 101: 11815-11820.CrossRef | Direct Link |
Morrow, C. and F. Fehler, 2004.
Marek's Disease: A Worldwide Problem. In: Marek's Disease: An Evolving Problem, Davison, F. and V. Nair (Eds.). Elsevier Academic Press, London, pp: 49-61
Murata, S., K.S. Chang, S.I. Lee, S. Konnai, M. Onuma and K. Ohashi, 2007.
Development of a nested polymerase chain reaction method to detect oncogenic Marek's disease virus from feather tips. J. Vet. Diagn. Invest., 19: 471-478.PubMed | Direct Link |
Nair, V., 2005.
Evolution of Marek's disease: A paradigm for incessant race between the pathogen and the host. Vet. J., 170: 175-183.CrossRef | Direct Link |
Notomi, T., H. Okayama, H. Masubuchi, T. Yonekawa, K. Watanabe, N. Amino and T. Hase, 2000.
Loop-mediated isothermal amplification of DNA. Nucl. Acids Res., 28: e63-e63.CrossRef |
Okazaki, W., H.G. Purchase and B.R. Burmester, 1970.
Protection against Marek's disease by vaccination with a herpesvirus of turkeys. Avian Dis., 14: 413-429.Direct Link |
Okwor, E.C. and D.C. Eze, 2011.
Outbreak and persistence of mareks disease in batches of birds reared in a poultry farm located in Nsukka, South East Nigeria. Int. J. Poult. Sci., 10: 617-620.CrossRef | Direct Link |
Powell, P.C. and F. Lombardini, 1986.
Isolation of very virulent pathotypes of Marek's disease virus from vaccinated chickens in Europe. Vet. Record, 118: 688-691.CrossRef | Direct Link |
Raja, A., G. Dhinakar-Raj, P. Bhuvaneswari, C. Balachand-Ran and K. Kumanan, 2009.
Detection of virulent MD virus in poultry in India. Acta Virol., 53: 255-260.CrossRef | Direct Link |
Rajkhowa, T.K., 2005.
Acute Marek's disease outbreak in commercial chicken in Aizawl Mizoram. Indian J. Vet. Pathol., 29: 127-128.
Schat, A.K. and V. Nair, 2008.
Marek's Disease. In: Diseases of Poultry, Saif, Y.M., A.M. Fadly, J.R. Glisson, L.R. McDougald, L.K. Nolan and D.E. Swayne (Eds.). 12th Edn., Blackwell Publishing, Iowa, pp: 452-512
Venugopal, K., K. Howes, D.M.J. Flannery and L.N. Payne, 2000.
Subgroup J avian leucosis virus infection in turkeys: Induction of rapid onset tumours by acutely transforming virus strain 966. Avian Pathol., 29: 319-325.CrossRef | Direct Link |
Wei, X., X. Shi, Y. Zhao, J. Zhang and M. Wang et al
Development of a rapid and specific loop-mediated isothermal amplification detection method that targets Marek's disease virus meq gene. J. Virol. Methods, 183: 196-200.CrossRef | Direct Link |
Witter, R.L., B.W. Calnek, C. Buscaglia, I.M. Gimeno and K.A. Schat, 2005.
Classification of Mareks disease viruses according to pathotype: Philosophy and methodology. Avian Pathol., 34: 75-90.CrossRef |
Witter, R.L., K. Nazerian, H.G. Purchase and G.H. Burgoyne, 1970.
Isolation from turkeys of a cell-associated herpesvirus antigenically related to Marek's disease virus. Am. J. Vet. Res., 31: 525-538.Direct Link |
Witter, R.L., 1998.
Control strategies for Marek's disease: A perspective for the future. Poultry Sci., 77: 1197-1203.Direct Link |
Witter, R.L., 2001.
Protective efficacy of Marek's disease vaccines. Curr. Top. Microbiol. Immunol., 255: 57-90.
Wozniakowski, G., E. Samorek-Salamonowicz and W. Kozdrun, 2011.
Rapid detection of Marek's disease virus in feather follicles by loop-mediated amplification. Avian Dis., 55: 462-467.PubMed | Direct Link |
Zelnik, V., 2004.
Diagnosis of Marek's Disease. In: Marek's Disease: An Evolving Problem, Davison, F. and V. Nair (Eds.). Elsevier Academic Press, London, pp: 157-167
Zhu, G.S., T. Ojima, T. Hironaka, T. Ihara and N. Mizukoshi et al
Differentiation of oncogenic and nononcogenic strains of Marek's disease virus type 1 by using polymerase chain reaction DNA amplification. Avian Dis., 36: 637-645.PubMed | Direct Link |
Kataria, J.M., C.M. Mohan, S. Dey, B.B. Dash and K. Dhama, 2005.
Diagnosis and immunoprophylaxis of economically important poultry diseases: A review. Indian J. Anim. Sci., 75: 555-567.Direct Link |
Li, Y., A. Sun, S. Su, P. Zhao, Z. Cui and H. Zhu, 2011.
Deletion of the Meq gene significantly decreases immunosuppression in chickens caused by pathogenic Marek's disease virus. Virol. J., Vol. 8. CrossRef | Direct Link |